A fire accident that occurred at the Serum Institute of India’s (SII) facility in the state of Maharashtra has claimed the lives of five people.

After the fire broke out, four others were evacuated from the building in the SII’s Manjari premises.

SII is manufacturing the Oxford-AstraZeneca Covid-19 vaccine, Covishield.

The vaccine manufacturer said it would not affect the production of the AstraZeneca coronavirus vaccination, Reuters quoted a government official as saying.

SII CEO Adar Poonawalla said on Twitter: “I would like to reassure all governments and the public that there would be no loss of Covishield production due to multiple production buildings that I had kept in reserve to deal with such contingencies at Serum Institute of India.”

According to sources, the affected plant is a kilometre away from the Covishield manufacturing unit.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

TIMESNOWNEWS reported that four people were evacuated from the fourth and fifth floor of the SEZ 3 building after a fire broke out supposedly due to an electrical fault.

The blaze at the SII plant is now under control.

The company, which licensed the vaccination, was also planning to start stockpiling up to 50 million doses a month of Novavax’s vaccine candidate from around April.